# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Zimmer Biomet receives an upgrade from Argus Research due to new product launches and strategic acquisitions.
Argus Research analyst David Toung upgrades Zimmer Biomet Holdings (NYSE:ZBH) from Hold to Buy and announces $150 price target.
Needham analyst Mike Matson reiterates Zimmer Biomet Holdings (NYSE:ZBH) with a Hold.
Truist Securities analyst Richard Newitter maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Hold and lowers the price targ...
Oppenheimer analyst Steven Lichtman maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Outperform and raises the price targe...
Zimmer Biomet beats Q1 earnings and sales estimates, with adjusted EPS at $1.94 and quarterly sales hitting $1.889 billion, pro...
Needham analyst Mike Matson reiterates Zimmer Biomet Holdings (NYSE:ZBH) with a Hold.